Navigation Links
Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008
Date:6/24/2008

ceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that include the word "potential". Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management's expectations and affect the forward-looking statements include but are not be limit
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
2. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
3. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
4. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
5. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
6. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
7. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
8. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
9. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia ... mercato europeo in occasione di Hi Europe 2014 (dal ... Si tratta della curcumina con la maggiore ... (senza cristalli) e ingredienti approvati dalle norme europee. ... spezia della pianta curcumina ( Curcuma longa ) che ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, ... G.K. Butterfield (D-NC) took a bold bipartisan ... by introducing the OPEN Act. Original co-sponsors of ... (D-FL). The Act will incentivize drug makers and ... rare diseases and pediatric cancers, which opens the ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... like Jack Welch and Larry Bossidy have been lionized ... attitude, relentless focus on bottom line performance and stellar ... run offer many valuable lessons, the management philosophies they ... for every company. Super Jacks rank and yank approach ...
... Engineering and Testing Services and Underwriters Laboratories have ... equipment building systems (NEBS) tests for telecommunications suppliers. ... such as seismic and transportation vibration, heat, humidity, ... not-for-profit product testing company, will provide customers of ...
... to be fooled by first impressions. And I have to admit ... Confoti in the January 2002 issue of DEMOletter, I was rather ... over the Internet. Dot-com businesses were imploding left and right ... site wouldn't be around for long. , ,I couldn't have been ...
Cached Biology Technology:Seven leadership lessons of Next Generation Companies 2Seven leadership lessons of Next Generation Companies 3Confoti: Revisiting a dotcom business model 2Confoti: Revisiting a dotcom business model 3Confoti: Revisiting a dotcom business model 4Confoti: Revisiting a dotcom business model 5
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... for a predator. Except when that predator runs so fast ... to its size, is the fastest creature on Earth. Some ... second (at about five miles per hour). The fastest human ... gold from the tiger beetle, a person would have to ... has a problem. At peak speeds, everything becomes a blur. ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... as earth -- and amylophagy, eating raw starches -- are ... 180 species of animals are also known to engage in ... appearing Oct. 17 in the online journal Public Library of ... Madagascar. It is one of only a few studies to ...
... of scientists searching for genes that determine the susceptibility and ... a five-year renewal grant of $4.3 million from the National ... John Reveille, M.D., of The University of Texas Health Science ... to this arthritic condition known as ankylosing spondylitis and hopes ...
... of Washington scientists have succeeded in removing the extra ... a person with Down,s syndrome. In Down syndrome, ... rather than the usual pair. A triplicate of ... trisomy. Trisomies account for almost one-quarter of pregnancy loss ...
Cached Biology News:Study documents eating of soil, raw starch in Madagascar 2Renewal grant supports genetic research into arthritis of the spine 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3
... The Universal Vacuum System UVS400 is ... system. The UVS400 combines a refrigerated vapor ... in a single integrated unit. The easy-to-use, ... recovered solvent into single jar for easy ...
... FastPrep System combines 2 products into 1:, ... A molecular isolation kit , ,The ... machine and Qbiogene/BIO101 System Matrix and Isolation ... individual micro tubes eliminating the use of ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
... is a fully flexible quadrupole MS detector ... high-speed HPLC, 1-D and 2-D LC, as ... It incorporates a drying gas system to ... sensitivity, especially for low-to-medium polarity compounds, while ...
Biology Products: